NCT03383016

Brief Summary

The risk of prostate cancer is associated with lifestyle habits, such as diet and physical activity. Indeed, results of numerous studies suggest links between obesity, diabetes, inflammation and androgen and estrogen metabolism in the pathogenesis of prostate cancer. The goal of BIOCaPPE study (Biomarkers and Prostate Cancer/ Prevention and Environment) is to identify biomarkers of prostate cancer risk that are potentially modifiable by environmental exposures (e.g. diet and physical activity). A selection of few of the most promising biological markers will be evaluated in a cohort of more than 2000 men at high-risk of prostate cancer. Such biomarkers would provide a practical approach to identify men at high risk of prostate cancer who could benefit from interventions aiming at reducing their risk. The biomarkers would also be useful to monitor the efficacy of the interventions on patient's lifestyle.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,053

participants targeted

Target at P75+ for all trials

Timeline
51mo left

Started Jun 2013

Longer than P75 for all trials

Geographic Reach
1 country

4 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress76%
Jun 2013Sep 2030

Study Start

First participant enrolled

June 20, 2013

Completed
4.5 years until next milestone

First Submitted

Initial submission to the registry

December 5, 2017

Completed
21 days until next milestone

First Posted

Study publicly available on registry

December 26, 2017

Completed
4.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 23, 2022

Completed
7.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2030

Expected
Last Updated

December 30, 2025

Status Verified

December 1, 2025

Enrollment Period

9.3 years

First QC Date

December 5, 2017

Last Update Submit

December 22, 2025

Conditions

Keywords

Prostate cancer riskEnvironmental risk factorsBiomarkersInflammation and prostate cancer

Outcome Measures

Primary Outcomes (1)

  • Biomarkers and modifiable exposure environment

    Assess the association between five candidate biological markers potentially modifiable by environmental exposures, mainly diet and physical activity, with the two-year risk of prostate cancer in men at risk for prostate cancer as previously defined.

    An average of 2 years

Secondary Outcomes (1)

  • Study biobank

    Through study completion, every year up to 2 years

Study Arms (1)

Men at high-rik of prostate cancer

Lifestyle questionnaires such as diet questionnaire, physical activities questionnaires, quality of life , Follows up 1 year and 2 years after the enrollment, Anthropometric measures during the first visit , Blood withdrawal for laboratory biomarkers analysis After 2 years, proposal for a 2-year end-of-study prostate biopsy to assess the presence or absence of prostate cancer.

Other: Lifestyle questionnairesDiagnostic Test: Prostate Biopsy

Interventions

Also known as: Blood withdrawal for Laboratory biomarkers analysis, Anthropometric measures
Men at high-rik of prostate cancer
Prostate BiopsyDIAGNOSTIC_TEST

Possible follow-up by an urologist at 1 year and 2 years after recruitment. After 2 years, proposal for a 2-year end-of-study prostate biopsy to assess the presence or absence of prostate cancer.

Also known as: follow-up by an urologist
Men at high-rik of prostate cancer

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Eligible participants for this prospective cohort study are men at risk for prostate cancer.

You may qualify if:

  • Group 1: A first negative prostate biopsy within 6 months
  • Group 2: serum-PSA level between 2.5-10 ng/mL and no prior prostate biopsy

You may not qualify if:

  • Prostate cancer
  • Positive result for transurethral prostatic resection

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal

Montreal, Quebec, H2X 0A9, Canada

Location

McGill University Health Center

Montreal, Quebec, H4A 3J1, Canada

Location

CHU de Quebec- Université Laval

Québec, Quebec, G1R3S1, Canada

Location

Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Sherbrooke, Quebec, J1H 5N4, Canada

Location

Biospecimen

Retention: SAMPLES WITH DNA

serum, plasma, whole blood and blood DNA samples and excess tissue collected from prostate biopsy or prostate surgery

MeSH Terms

Conditions

Prostatic NeoplasmsInflammation

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Vincent FRADET, MD, PhD

    CHU de Québec-Université Laval

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 5, 2017

First Posted

December 26, 2017

Study Start

June 20, 2013

Primary Completion

September 23, 2022

Study Completion (Estimated)

September 1, 2030

Last Updated

December 30, 2025

Record last verified: 2025-12

Locations